NASH: The Next Big, Fatty Drug for the Pharmaceutical Industry

Posted

NASH drug development

With a global market estimated at $35 billion, developing a drug to treat a form of fatty liver disease called non-alcoholic steatohepatitis or NASH could be the next big thing for the pharmaceutical industry. Attention to this disease is happening because of declining drug development elsewhere, the obesity epidemic and the ravaging impact on as… Read more »